That question guided a recent Institute for Tissue Regeneration & Repair webinar sponsored by CuraMedix, featuring Dr. Eric Lullove, a board-certified podiatric physician, surgeon, and Chief Executive and Medical Officer of the West Boca Center for Wound Healing in Coconut Creek, Florida. With more than 20 years of clinical and surgical experience, Dr. Lullove has dedicated his work to wound care, limb salvage, and emerging treatment technologies.
Dr. Lullove explained his research on the potential of combining Extracorporeal Shockwave Therapy (ESWT) and Extracorporeal Magnetotransduction Therapy (EMTT®) to support healing in persistent wounds. His findings offer encouraging signs of wound closure and pain reduction, opening new possibilities about how these technologies could fit into multimodal wound management.
Watch Dr. Lullove’s full presentation here, or keep reading for key findings and clinical insights from the webinar.
Want to take a deeper dive into the science? Explore the full peer-reviewed study, by Dr. Lullove and co-authored with Dr. Karsten Knobloch, including the methodology, treatment parameters, and clinical outcomes.
In Dr. Lullove’s study, wounds averaged less than three square centimeters, yet patients reported average pain levels above eight out of ten. With a mean age of 82, these patients were also managing venous insufficiency, hypertension, and, in many cases, diabetes.
Traditional treatment approaches all have important roles to play: dressings can protect the wound, debridement removes damaged tissue, and compression helps manage swelling associated with venous disease. Yet in many cases, healing can remain stalled, prolonging both discomfort and the need for ongoing care.
Shockwave and EMTT deliver different forms of energy to tissue. Shockwave uses acoustic pressure pulses to create a mechanical stimulus that cells respond to through a process called mechanotransduction. In wound care, this treatment is used to encourage repair activity, including new blood vessel formation and tissue growth.
EMTT uses rapidly changing magnetic fields to induce electrical activity within tissue. Its applicator does not need direct contact with the patient, allowing treatment to take place while a wound remains dressed.
A study of 86 patients with rotator cuff tendinopathy had reported better pain and shoulder-function outcomes at 24 weeks when EMTT was added to Shockwave. This research provided a rationale for Dr. Lullove to explore the combination in wound care.
Dr. Lullove used the C-ACTOR handpiece, which distributes energy across a broad, shallow treatment area suited to the wound bed, in addition to EMTT.
Combining these treatments as part of a multimodal treatment approach allows a medical professional to use these different stimuli to support complementary aspects of repair. As Dr. Lullove explained, “They enter the cell at different doors, but they appear to arrive in the same room together.”
The treatment course was incorporated into regular dressing visits as follows:
Dr. Lullove deliberately departed from the usual care route by withholding compression to observe the response to the energy-based treatments without that additional intervention, while emphasizing that compression remains standard care for wounds with a venous component.
For Dr. Lullove, these findings are part of an ongoing effort to refine how energy-based treatments can help his patients. “I’m still learning how to manipulate the energy fields and how to manipulate the devices so that I can try to get the best therapeutic effect for my patients.” Continued research and shared experience among clinicians will help clarify where these technologies can make the greatest contribution to wound care.
Thank you to Dr. Lullove for sharing his research and clinical insights with the CuraMedix community. Watch the full webinar for a closer look at the study and its implications for wound care.
If you are interested in a broader look at the research on Shockwave in wound care, our Wound Care Resource Hub is a great place to get started.
Choosing the right devices for your practice starts with understanding your clinical goals and the applications you want to support. An experienced Shockwave partner can help you evaluate those options and provide the training and ongoing support needed to integrate them into patient care.
To explore how Shockwave and EMTT could fit into your practice, contact the CuraMedix team.
Shockwave is being studied as an additional treatment for wounds that have stopped progressing with standard care. Research has reported encouraging healing outcomes, although its role varies by wound type and requires further investigation.
Shockwave uses acoustic pressure pulses, while EMTT uses magnetic fields to stimulate tissue. Combining them may support repair through complementary pathways, but research is still needed to determine whether the combination improves outcomes over either technology alone.
A small study of 15 patients with persistent lower-extremity wounds after Mohs surgery reported approximately 70% reduction in average wound area and 72% reduction in average pain scores after four weeks. Thirteen wounds closed by eight weeks. Patients also received ongoing wound care, and the study had no control group.
No. Shockwave and EMTT are being explored within comprehensive wound management. Appropriate dressings, debridement, circulation and infection assessment, and compression when indicated remain important parts of care.